Early and late effects of hyperbaric oxygen treatment on oxidative stress parameters in diabetic patients

Physiological Research

Volumn 57, Issue 1, 2008, Pages 41-47

  Gürdöl, Figen ^a   Cimsit M ^a   Oner Iyidogan Y ^b   Korpinar ^a   Yalcinkaya S ^a   Kocak H ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Advanced oxidation protein products; Diabetic foot; Hyperbaric oxygen; Isoprostanes; Malondialdehyde

Indexed keywords

8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIOXIDANT; BIOLOGICAL MARKER; DRUG DERIVATIVE; MALONALDEHYDE; PLASMA PROTEIN; PROSTAGLANDIN F2 ALPHA; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ARTICLE; BLOOD; DIABETIC FOOT; FEMALE; HUMAN; HYPERBARIC OXYGEN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD PROTEINS; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; DINOPROST; FEMALE; HUMANS; HYPERBARIC OXYGENATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 45349088830     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. ABIDIA A, LADEN G, KUHAN G, JOHNSON BF, WILKINSON AR, RENWICK PM, MASSON EA, MCCOLLUM PT: The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg 25: 513-518, 2003.
2. ABOU-SEIF MA, YOUSSEF AA: Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 346: 161-170, 2004.
3. BASU S, HELMERSSON J: Factors regulating isoprostane formation in vivo. Antioxid Redox Signal 7: 221-235, 2005.
4. BUEGE JA, AUST JD: Microsomal lipid peroxidation. Methods Enzymol 52: 302-310, 1978.
5. COMPORTI M, AREZZINI B, SIGNORINI C, SGHERRI C, MONACO B, GARDI C: F2-isoprostanes stimulate collagen synthesis in activated hepatic stellate cells: a link with liver fibrosis? Lab Invest 85: 1381-1391, 2005.
6. DA ROS R, ASSALONI R, CERIELLO A: Antioxidant therapy in diabetic complications: what is new? Curr Vasc Pharmacol 2: 335-341, 2004.
7. DALTON TP, SHERTZER HG, PUGA A: Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 39: 67-101, 1999.
8. DAVI G, FALCO A, PATRONO C: Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 7: 256-268, 2005.
9. DE CRISTOFARO R, ROCCA B, VITACOLONNA E, FALCO A, MARCHESANI P, CIABATTONI G, LANDOLFI R, PATRONO C, DAVI G: Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 1: 250-256, 2003.
10. DENNOG C, RADERMACHER P, BARNETT YA, SPEIT G: Antioxidant status in humans after exposure to hyperbaric oxygen. Mutat Res 428: 83-89, 1999.
11. EKEN A, AYDIN A, SAYAL A, USTUNDAG A, DUYDU, Y. DUNDAR K: The effects of hyperbaric oxygen treatment on oxidative stress and SCE frequencies in humans. Clin Biochem 38: 1133-1137, 2005.
12. FELDMEIER JJ: Hyperbaric oxygen: indications and results. The Hyperbaric Oxygen Therapy Committee Report. Undersea and Hyperbaric Medical Society. Maryland, USA, 2003.
13. GIL-DEL VALLE L, MILIAN LC, TOLEDO A, VILARO N, TAPANES R, OTERO MA: Altered redox status in patients with diabetes mellitus type I. Pharmacol Res 51: 375-380, 2005.
14. GILLERY P: Advanced glycation end products (AGEs), free radicals and diabetes (in French). J Soc Biol 195: 387-390, 2001.
15. GREGOREVIC P, LYNCH GS, WILLIAMS DA: Hyperbaric oxygen modulates antioxidant enzyme activity in rat skeletal muscles. Eur J Appl Physiol 86: 24-27, 2001.
16. HARABIN AL, BRAISTED JC, FLYNN ET: Response of antioxidant enzymes to intermittent and continuous hyperbaric oxygen. J Appl Physiol 69: 328-335, 1990.
17. HERRLICH P, BOHMER FD: Redox regulation of signal transduction in mammalian cells. Biochem Pharmacol 59: 35-41, 2000.
18. HINK J, JANSEN E: Are superoxide and/or hydrogen peroxide responsible for some of the beneficial effects of hyperbaric oxygen therapy? Med Hypotheses 57: 764-769, 2001.
19. JAMIESON DD: Lipid peroxidation in brain and lungs from mice exposed to hyperoxia. Biochem Pharmacol 41: 749-756, 1991.
20. KALANI M, Jocombining double acute accentRNESKOG G; NADERI N, LIND F, BRISMAR K: Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications 16: 153-158, 2002.
21. KALOUSOVÁ M, ŠKRHA J, ZIMA T: Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51: 597-604, 2002.
22. KIM CH, CHOI H, CHUN YS, KIM GT, PARK JW, KIM MS: Hyperbaric oxygenation pretreatment induces catalase and reduces infarct size in ischemic rat myocardium. Pflugers Arch 442: 519-525, 2001.
23. LIN HC, WAN FJ, WU CC, TUNG CS, WU TH: Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats. Eur J Pharmacol 508: 249-254, 2005.
24. MARTIN-GALLAN P, CARRASCOSA A, GUSSINYE M, DOMINGUEZ C: Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 34: 1563-1574, 2003.
25. MATHIEU D, LINKE JC, WATTEL F: Non-healing wounds. In: Handbook on Hyperbaric Medicine. D. MATHIEU (ed), Springer, Netherlands, 2006, pp 401-427.
26. NIE H, XIONG L, LAO N, CHEN S, XU N, ZHU Z: Hyperbaric oxygen preconditioning induces tolerance against spinal cord ischemia by upregulation of antioxidant enzymes in rabbits. J Cereb Blood Flow Metab 26: 666-674, 2006.
27. OPARA EC: Oxidative stress, micronutrients, diabetes mellitus and its complications. J R Soc Health 122: 28-34, 2002.
28. OTER S, KORKMAZ A, TOPAL T, OZCAN O, SADIR S, OZLER M, OGUR R, BILGIC H: Correlation between hyperbaric oxygen exposure pressures and oxidative parameters in rat lung, brain, and erythrocytes. Clin Biochem 38: 706-711, 2005.
29. ROBERTS, LJ, MORROW JD: Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28: 505-513, 2000.
30. ROSETTE C, KARIN M: Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274: 1194-1197, 1996.
31. ROTHFUSS A, DENNOG C, SPEIT G: Adaptive protection against the induction of oxidative DNA damage after hyperbaric oxygen treatment. Carcinogenesis 19: 1913-1917, 1998.
32. TSIARA S, ELISAF M, MIKHAILIDIS DP: Early vascular benefits of statin therapy. Curr Med Res Opin 19: 540-556, 2003.
33. WATTEL F: European Committee Consensus Conference on Hyperbaric Oxygen in the Treatment of Foot Lesions in Diabetic Patients. ECHM. Glaxo-Welcome, France, 1998.
34. WITKO-SARSAT V, FRIEDLANDER M, CAPEILLERE-BLANDIN C, NGUYEN-KHOA T, NGUYEN AT, ZINGRAFF J, JUNGERS P, DESCAMPS-LATSCHA B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313, 1996.
35. WITKO-SARSAT V, GAUSSON V, NGUYEN AT, TOUAM M, DRUEKE T, SANTANGELO F, DESCAMPSLATSCHA B: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 64: 82-91, 2003.
36. YOGARATNAM JZ, LADEN G, MADDEN LA, SEYMOUR AM, GUVENDIK L, COWEN M, GREENMAN J, CALE A GRIFFIN S: Hyperbaric oxygen: a new drug in myocardial revascularization and protection? Cardiovasc Revasc Med 7: 146-154, 2006.
37. YU SY, CHIU JH, YANG SD, YU HY, HSIEH CC, CHEN PJ, LUI WY, WU CW: Preconditioned hyperbaric oxygenation protects the liver against ischemia-reperfusion injury in rats. J Surg Res 128: 28-36, 2005.